• Users Online: 279
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
Year : 2015  |  Volume : 21  |  Issue : 2  |  Page : 55-59

Serum lipoxin A4 as a biomarker for systemic lupus erythematosus

1 Department of Rheumatology & Rehabilitation, Faculty of Medicine, Cairo University, Cairo, Egypt
2 Department of Clinical & Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt

Correspondence Address:
Noha Mahmoud Abd El Baky
Department of Rheumatology & Rehabilitation, Faculty of Medicine, Cairo University, Cairo 02020
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/1687-4625.162390

Rights and Permissions

Introduction Systemic lupus erythematosus (SLE) is an immune-complex mediated autoimmune disease characterized by protean clinical manifestations and fluctuating disease course. It was proposed that progression and flares of lupus and lupus nephritis are due to decreased production of lipoxin A4 (LXA4) and enhanced production of leukotrienes by the renal tissue and/or infiltrating leukocytes and macrophages. Objective The aim of this study was to assess the levels of serum LXA4 in SLE patients and in healthy controls, and to correlate them with various clinical and laboratory data as well as renal biopsy and disease activity indices. Patients and methods Forty adult female SLE patients were included in this study. The SLE patients were divided into two groups: group I included 20 patients without nephritis and group II included 20 patients with nephritis. Forty apparently healthy age-matched women served as the control group. Patients and controls were assessed for serum LXA4 using enzyme linked immunosorbent assay. Disease activity was assessed using systemic lupus erythematosus desease activity index (SLEDAI) and renal SLEDAI. Renal biopsy was performed for patients with lupus nephritis. Results SLE patients showed a higher median level of serum LXA4 compared with the control group (0.24 vs. 0.15 ng/ml), but with no significant statistical difference (P = 0.097). Moreover, there was no statistically significant difference in serum LXA4 between SLE patients with and without nephritis and the control group (P = 0.142). There was no significant correlation between serum LXA4 and various clinical and laboratory data, as well as renal biopsy and disease activity index. Conclusion LXA4 was suggested to be an important biomarker to search for in SLE. Our study showed no significant statistical difference between SLE patients and the control group as regards serum LXA4. Assessment of urinary LXA4 is recommended as it may be more valuable than serum LXA4 in reflecting organ affection in SLE, as well as disease activity, and comparing it with serum LXA4 level.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded191    
    Comments [Add]    

Recommend this journal